644 related articles for article (PubMed ID: 27996251)
1. Introducing the 4-Phenyl-1,2,3-Triazole Moiety as a Versatile Scaffold for the Development of Cytotoxic Ruthenium(II) and Osmium(II) Arene Cyclometalates.
Riedl CA; Flocke LS; Hejl M; Roller A; Klose MH; Jakupec MA; Kandioller W; Keppler BK
Inorg Chem; 2017 Jan; 56(1):528-541. PubMed ID: 27996251
[TBL] [Abstract][Full Text] [Related]
2. Piano-Stool Ruthenium(II) Complexes with Delayed Cytotoxic Activity: Origin of the Lag Time.
Rafols L; Josa D; Aguilà D; Barrios LA; Roubeau O; Cirera J; Soto-Cerrato V; Pérez-Tomás R; Martínez M; Grabulosa A; Gamez P
Inorg Chem; 2021 Jun; 60(11):7974-7990. PubMed ID: 33979132
[TBL] [Abstract][Full Text] [Related]
3. N- and S-donor leaving groups in triazole-based ruthena(ii)cycles: potent anticancer activity, selective activation, and mode of action studies.
Riedl CA; Hejl M; Klose MHM; Roller A; Jakupec MA; Kandioller W; Keppler BK
Dalton Trans; 2018 Mar; 47(13):4625-4638. PubMed ID: 29520401
[TBL] [Abstract][Full Text] [Related]
4. Highly Cytotoxic Ruthenium(II)-Arene Complexes from Bulky 1-Pyrenylphosphane Ligands.
Brissos RF; Clavero P; Gallen A; Grabulosa A; Barrios LA; Caballero AB; Korrodi-Gregório L; Pérez-Tomás R; Muller G; Soto-Cerrato V; Gamez P
Inorg Chem; 2018 Dec; 57(23):14786-14797. PubMed ID: 30444630
[TBL] [Abstract][Full Text] [Related]
5. Triazole-Based Half-Sandwich Ruthenium(II) Compounds: From
Lenis-Rojas OA; Cabral R; Carvalho B; Friães S; Roma-Rodrigues C; Fernández JAA; Vila SF; Sanchez L; Gomes CSB; Fernandes AR; Royo B
Inorg Chem; 2021 Jun; 60(11):8011-8026. PubMed ID: 33973771
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, structure and anticancer properties of new biotin- and morpholine-functionalized ruthenium and osmium half-sandwich complexes.
Marloye M; Inam H; Moore CJ; Debaille V; Pritchard JR; Gelbcke M; Meyer F; Dufrasne F; Berger G
J Biol Inorg Chem; 2021 Aug; 26(5):535-549. PubMed ID: 34173882
[TBL] [Abstract][Full Text] [Related]
7. Identification of the structural determinants for anticancer activity of a ruthenium arene peptide conjugate.
Meier SM; Novak M; Kandioller W; Jakupec MA; Arion VB; Metzler-Nolte N; Keppler BK; Hartinger CG
Chemistry; 2013 Jul; 19(28):9297-307. PubMed ID: 23712572
[TBL] [Abstract][Full Text] [Related]
8. Striking difference in antiproliferative activity of ruthenium- and osmium-nitrosyl complexes with azole heterocycles.
Büchel GE; Gavriluta A; Novak M; Meier SM; Jakupec MA; Cuzan O; Turta C; Tommasino JB; Jeanneau E; Novitchi G; Luneau D; Arion VB
Inorg Chem; 2013 Jun; 52(11):6273-85. PubMed ID: 23659478
[TBL] [Abstract][Full Text] [Related]
9. Novel C,N-Cyclometalated Benzimidazole Ruthenium(II) and Iridium(III) Complexes as Antitumor and Antiangiogenic Agents: A Structure-Activity Relationship Study.
Yellol J; Pérez SA; Buceta A; Yellol G; Donaire A; Szumlas P; Bednarski PJ; Makhloufi G; Janiak C; Espinosa A; Ruiz J
J Med Chem; 2015 Sep; 58(18):7310-27. PubMed ID: 26313136
[TBL] [Abstract][Full Text] [Related]
10. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
[TBL] [Abstract][Full Text] [Related]
11. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands.
Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G
Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401
[TBL] [Abstract][Full Text] [Related]
12. 4β-amidotriazole linked podophyllotoxin congeners: DNA topoisomerase-IIα inhibition and potential anticancer agents for prostate cancer.
Reddy VG; Bonam SR; Reddy TS; Akunuri R; Naidu VGM; Nayak VL; Bhargava SK; Kumar HMS; Srihari P; Kamal A
Eur J Med Chem; 2018 Jan; 144():595-611. PubMed ID: 29289884
[TBL] [Abstract][Full Text] [Related]
13. Biological properties of novel ruthenium- and osmium-nitrosyl complexes with azole heterocycles.
Novak MS; Büchel GE; Keppler BK; Jakupec MA
J Biol Inorg Chem; 2016 Jun; 21(3):347-56. PubMed ID: 26961253
[TBL] [Abstract][Full Text] [Related]
14. A SAR study of novel antiproliferative ruthenium and osmium complexes with quinoxalinone ligands in human cancer cell lines.
Ginzinger W; Mühlgassner G; Arion VB; Jakupec MA; Roller A; Galanski MS; Reithofer M; Berger W; Keppler BK
J Med Chem; 2012 Apr; 55(7):3398-413. PubMed ID: 22417128
[TBL] [Abstract][Full Text] [Related]
15. Ru
Lenis-Rojas OA; Robalo MP; Tomaz AI; Carvalho A; Fernandes AR; Marques F; Folgueira M; Yáñez J; Vázquez-García D; López Torres M; Fernández A; Fernández JJ
Inorg Chem; 2018 Nov; 57(21):13150-13166. PubMed ID: 30339386
[TBL] [Abstract][Full Text] [Related]
16. Ruthenium(II) and osmium(II) 1,2,3-triazolylidene organometallics: a preliminary investigation into the biological activity of 'click' carbene complexes.
Kilpin KJ; Crot S; Riedel T; Kitchen JA; Dyson PJ
Dalton Trans; 2014 Jan; 43(3):1443-8. PubMed ID: 24201979
[TBL] [Abstract][Full Text] [Related]
17. Highly Cytotoxic Osmium(II) Compounds and Their Ruthenium(II) Analogues Targeting Ovarian Carcinoma Cell Lines and Evading Cisplatin Resistance Mechanisms.
Hildebrandt J; Häfner N; Kritsch D; Görls H; Dürst M; Runnebaum IB; Weigand W
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563367
[TBL] [Abstract][Full Text] [Related]
18. Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity.
Kassab AE; Gedawy EM
Eur J Med Chem; 2018 Apr; 150():403-418. PubMed ID: 29547830
[TBL] [Abstract][Full Text] [Related]
19. Determination of in vitro absorption in Caco-2 monolayers of anticancer Ru(II)-based complexes acting as dual human topoisomerase and PARP inhibitors.
de Camargo MS; De Grandis RA; da Silva MM; da Silva PB; Santoni MM; Eismann CE; Menegário AA; Cominetti MR; Zanelli CF; Pavan FR; Batista AA
Biometals; 2019 Feb; 32(1):89-100. PubMed ID: 30506342
[TBL] [Abstract][Full Text] [Related]
20. New organoruthenium compounds with pyrido[2',3':5,6]pyrazino[2,3-f][1, 10]phenanthroline: synthesis, characterization, cytotoxicity, and investigation of mechanism of action.
Pavlović M; Nikolić S; Gligorijević N; Dojčinović B; Aranđelović S; Grgurić-Šipka S; Radulović S
J Biol Inorg Chem; 2019 Mar; 24(2):297-310. PubMed ID: 30762123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]